Summary of clinical trials referenced in this review
HD indicates high-dose; HR; high risk; IT, intrathecal; IV, intravenous; MR, medium risk; MTX, methotrexate; RER, rapid early responder; SR, standard risk; triple IT, triple intrathecal therapy (hydrocortisone, cytarabine, and methotrexate); and VHR, very high risk.